Royalty Pharma Q2 results in focus as revenue dips from Q1

Royalty Pharma Plc will publish its second-quarter results before the market opens on Wednesday, August 5, with analysts expecting earnings of $1.29 per share on revenue of $800.1 million, a notable sequential decline from the $925 million received in the first quarter. The revenue forecast represents a 38.3% year-over-year increase but has fallen 5.74% over the past 60 days, while earnings-per-share estimates have declined 0.2% in the same period. Wall Street remains optimistic, with seven of nine analysts rating the stock a Buy and a consensus price target of $59.89, implying 4.8% upside from current levels around $57. Investors will focus on whether the expected Q2 weakness reflects normal quarterly variability in royalty payments or broader portfolio challenges. The company recently announced R&D co-financing agreements with Johnson & Johnson and Teva Pharmaceuticals, and acquired a stake in Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million in July. Management's commentary on achieving the raised 2026 full-year guidance of $3.325 billion to $3.45 billion in Portfolio Receipts will be crucial.